POLIVY PD.I.S.INF 140MG/VIAL Grčka - grčki - Εθνικός Οργανισμός Φαρμάκων

polivy pd.i.s.inf 140mg/vial

roche pharma ag, grenzach-wyhlen, germany emil-barell-strasse 1, d-79639, grenzach-wylhen - polatuzumab vedotin - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 140mg/vial - polatuzumab vedotin 140mg - polatuzumab vedotin

Minjuvi Europska Unija - grčki - EMA (European Medicines Agency)

minjuvi

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

TRODELVY PD.C.SO.IN 200 MG/VIAL Grčka - grčki - Εθνικός Οργανισμός Φαρμάκων

trodelvy pd.c.so.in 200 mg/vial

gilead sciences ireland uc, co. cork, ireland ida business and technology park, - co. cork - sacituzumab govitecan - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 200 mg/vial - sacituzumab govitecan 200mg - sacituzumab govitecan

Padcev Europska Unija - grčki - EMA (European Medicines Agency)

padcev

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Αντινεοπλασματικοί παράγοντες - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Lunsumio Europska Unija - grčki - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - Λέμφωμα, θυλακοειδής - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

EMPLICITI PD.C.SO.IN 400 MG/VIAL Grčka - grčki - Εθνικός Οργανισμός Φαρμάκων

empliciti pd.c.so.in 400 mg/vial

bristol-myers squibb pharma eeig, ireland plaza 254, blanchardstown corporate park 2, d15t867 dublin 15 - elotuzumab - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 400 mg/vial - elotuzumab 400mg - elotuzumab

EMPLICITI PD.C.SO.IN 300 MG/VIAL Grčka - grčki - Εθνικός Οργανισμός Φαρμάκων

empliciti pd.c.so.in 300 mg/vial

bristol-myers squibb pharma eeig, ireland plaza 254, blanchardstown corporate park 2, d15t867 dublin 15 - elotuzumab - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 300 mg/vial - elotuzumab 300mg - elotuzumab

MINJUVI PD.C.SO.IN 200 MG/VIAL Grčka - grčki - Εθνικός Οργανισμός Φαρμάκων

minjuvi pd.c.so.in 200 mg/vial

incyte biosciences distribution b.v., the netherlands paasheuvelweg 25, 1105 bp amsterdam - tafasitamab - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 200 mg/vial - tafasitamab 200mg - tafasitamab

RYBREVANT C/S.SOL.IN 350MG/7ML Grčka - grčki - Εθνικός Οργανισμός Φαρμάκων

rybrevant c/s.sol.in 350mg/7ml

janssen-cilag intern. nv.,belgium turnhoutseweg, 30, b-2340 beerse, - amivantamab - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 350mg/7ml - amivantamab 350mg - amivantamab

Imjudo Europska Unija - grčki - EMA (European Medicines Agency)

imjudo

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Αντινεοπλασματικοί παράγοντες - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.